Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) - SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CytomX ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc.

Though many biotech investment firms have recently raised new funds to support young drugmakers, they’re cautious in deploying that cash in a turbulent economic climate. That hesitance has given ...

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Dow Jones Top Company Headlines at 9 AM ET: Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings | Novo ... Eli Lilly reported higher profit and raised its outlook on surging demand for its ...

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise. The pharmaceutical company reported net income of $5.79 ...